CL-PTL-126: A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

February 24, 2019
Cancer - Ovarian, Cancer - Cervical
Principal Investigator: unassigned
Cancer, Ovarian, Ovarian Cancer, Cervical Cancer, Uterine cancer, Advanced Gynecological Cancer, Gynecological cancer, Phase 2, Phase II, Gradalis, Atezolizumab, Biomarker